Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Strong Bullish
88.5
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit declining as much as 13% this year.
Pulse AI Analysis
Pulse analysis not available yet. Click "Get Pulse" above.
This analysis was generated using Pulse AI, Glideslope's proprietary AI engine designed to interpret market sentiment and economic signals. Results are for informational purposes only and do not constitute financial advice.
